cannabinoids

News

Data backs Vertanical's cannabis therapy for back pain

A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.

News

Vertanical's chief executive, Dr Clemens Fischer

Vertanical's cannabis-based painkiller hits target in trials

A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.

News

Cannabinoids show promise in acute migraine clinical trial

Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine, according to a new clinical trial.

News

Harmony buys cannabidiol firm Zynerba in $200m deal

Neuroscience specialist Harmony Biosciences has agreed to acquire Zynerba, adding its cannabidiol (CBD) gel product Zygel for Fragile X syndrome and other rare neuropsychi

Partner Content

Partner Content

Registration is closing soon for SMi’s 22nd Annual Pain Ther...

Registrations Closing Soon

Data backs Vertanical's cannabis therapy for back pain

Vertanical's cannabis-based painkiller hits target in trials

Cannabinoids show promise in acute migraine clinical trial

Harmony buys cannabidiol firm Zynerba in $200m deal

Registration is closing soon for SMi’s 22nd Annual Pain Ther...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

cannabinoids

Editor's Picks